U.S. FDA approves new Bristol Myers cancer immunotherapy - Yahoo! Voices

The U.S. Food and Drug Administration approved relatlimab from a class known as LAG-3 inhibitors - short for lymphocyte-activation gene 3 - for use in...

(Reuters) - Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest f… [+1739 chars]

full article...